Pharmacokinetics (Drug Disposition)
Drug Absorption, Distribution and Elimination
Get a mental picture of what's going on "inside". (Think about anatomy and histology in terms of "how things work.")
Drugs MUST have some ability to dissolve in WATER to move around (be absorbed, reach sites of action). In almost all cases, drugs must also have a certain degree of lipid solubility to move around (leave and enter capillaries, enter and leave cells).
Solubility is a preference not an absolute. "Water Soluble", "Lipid Soluble"Drug effects are USUALLY proportional (though not always linear) to drug concentration at the site of action.
Drug concentrations in the blood stream (measured in either serum or plasma) are USUALLY proportional (and usually linear) to drug concentrations at the site of action.
Drug concentration in the blood stream is ALMOST ALWAYS an excellent predictor of drug action (either efficacy or toxicity) even though they may not be identical to the concentration in the target tissue.
Pharmacokinetics are the consequence of physiologic processes (that may or may not be altered by disease).
"Species differences in pharmacokinetics are the PRIMARY difference between Veterinary pharmacology and Human pharmacology". Disease-induced differences are the PRIMARY difference between basic and clinical pharmacology.Do you understand proportional? linear? equillibrium?
Routes of Administration (Drug Absorption)
General Principles
Drugs dissolve in body fluid (water).
Drugs enter the circulatory system as fluid enters the circulatory system.
Drugs must enter the circulatory system before they can be distributed to sights of action.
(Drugs for enteric effects are an obvious exception.)
Therefore, drugs are not IN the body until they are IN the bloodstream.
Oral Administration
Advantages
Convenient, cheap, no need for sterilization, variety of dose forms
(fast release tablets, capsules, enteric coated, layered tablets, slow release, suspensions, mixtures)
You can get the dose back if you move fast enough.
Disadvantages
Variability due to physiology, feeding, disease, etc.
Intractable patients
First-pass effect
Efficiently metabolized drugs eliminated by the liver before they reach the systemic circulation.
Table 1: Location of processes involved in the absorption of oral drugs.
Patient and Pharmaceutical Factors
Pill compression, coatings, suspending agents, etc.
GI transit time (too slow or too fast), inflammation, malabsorption syndromes
Regional differences
Stomach
mechanical preparation
"flat" absorptive surface
pH extreme
Rumenoreticulum
stratified squamous epithelium
pH varies with diet
metabolism by bacterial flora
significant volume of fluid compared to body water
Small Intestine
large absorptive surface
specialized absorptive functions
relatively neutral pH
Colon/Rectum
accessible
large absorptive surface
Intramuscular Administration
Advantages
More consistent absorption than oral or sub-cutaneous (below)
Depot or sustained effect possible (procaine penicillin G, methylprednisolone acetate, desoxycorticosterone pivalate)
Administration to unconscious, vomiting or fractious patients
Certainty of administration
Disadvantages
More difficult for owners (small patients)
Pain
Muscle Damage
Dose cannot be recovered.
Process
ANY of these processes can be "rate limiting" for absorption.
- Drug in suspension dissolves in tissue fluid (drug in solution only has to MIX with the tissue fluid).
- Drug in tissue fluid solution diffuses into capillaries
- Drug (in solution) in capillaries is carried to circulatory system.
Bolus injection roughly spherical
water soluble vehicle mixes with tissue fluid for rapid absorption. The drug is already dissolved in "water", so dissolution in tissue fluid is not rate-limiting. Entry of drug into circulatory system limited (only) by rate of blood flow to the tissue.
blood flow varies by body region/muscle group, so exercise may affect absorption ratelipid soluble vehicle The bolus remains relatively spherical. Mixing and dissolution in tissue fluid occurs from surface of bolus, so entry of drug into circulatory system limited by rate of drug "dissolution". (Movement from the "bolus" to the tissue fluid).
Occasionally, vehicle may be absorbed more rapidly than drug. Then the drug "falls" out of solution in the tissue and dissolves very slowly.Produces tissue residues
Reduces effect
Patient and Pharmaceutical Factors
Drug and vehicle solubility
pH extremes
Regional blood flow variability
Subcutaneous Administration
Advantages
Can be given by the owner (small patients)
Vasoconstrictor can be added to prolong effect at site of interest
Disadvantages
Variability
Process
Much like intramuscular (though the architecture of the tissue is much different)
Patient and Pharmaceutical Factors
More autonomic control over blood flow (than muscle)
dehydration, heat, cold, stress
Topical
Advantages
IF systemic therapy - easy painless application (e.g., mass medication of cattle)
IF skin therapy - reduced systemic effects / enhanced skin effects
Disadvantages
Patients groom themselves (topically applied, orally absorbed)
Toxic skin reactions
Variable blood flow to skin
COMPLEX relationship between drug, vehicle, skin physiology
Process
Diffusion through stratified epithelium
"Passage" through adnexal structures
Patient and Pharmaceutical Factors
Lipid solubility and molecule size
Skin hydration and abrasion
Area of application
Ambient and patient temperature
Be suspicious of topical formulations from compounding pharmacies. SEE:Hoffman SB, Yoder AR, Trepanier LA. Bioavailability of transdermal methimazole in a pluronic lecithin organogel (PLO) in healthy cats. J Vet Pharmacol Ther. 2002 Jun;25(3):189-93.
Vehicle effects
"like" vehicles retain drug on skin surface
(e.g., aqueous drug in aqueous vehicle, lipid drug in lipid vehicle)drugs in "unlike" vehicles leave the vehicle to move to skin
(e.g, aqueous drug in lipid suspension, lipid drug in aqueous suspension)
Intraperitoneal
Advantages
Larger absorptive surface area than IM / Subcutaneous
Disadvantages
Drugs or vehicles may cause peritonitis
Damage to organs by needles
Injection into organs
Process
Similar to subcutaneous
Greater blood flow
Less flow regulation
Patient and Pharmaceutical Factors
Generally restricted to laboratory animals
Intrathecal
Advantages
Direct delivery to site of action
Disadvantages
Difficult dose calculation
CSF volume is not proportional to body weightToxicity likely, and toxicity may be unusual
Introduce infection into a VERY bad location.
Process
Absorption is usually by diffusion and very slow
Intra-articular
Advantages
Direct delivery to site of action. High concentrations can be produced in the joint.
Disadvantages
It may be difficult to hit the joint space depending on the species (size of joint space).
Difficult dose calculation
Joint space volume depends on disease
Recommended doses tend to be larger than necessary.Irritation of joint surfaces/capsule (chemical effects, biochemical/physiologic effects.)
Introduce infection. (PSGAG - Adequan® - injections now generally get "antimicrobial chaser".)
Joint "flushes" don't count.
Process
Absorption from the site to systemic circulation is variable but often quite fast. Systemic concentrations of the drug may be produced. Effects in joint may not persist. (Drug and dose form dependent)
Intra-arterial
Advantages
Produce extremely high concentrations "pointed at" (this is not really targeting) the tissue of interest. Used primarily for anti-tumor therapy and infectious disease therapy when blood supply is questionable.
Disadvantages
Dose calculation is best guess.
Intra-arterial lines difficult to insert/maintain.
Dosing is still really systemic.
Limited number of efficacy studies (especially in animals)
Process
Produce AND SUSTAIN high blood-to-tissue gradient to increase tissue concentrations of drug. Requires sustained infusion or application of tourniquet following bolus dosing.
Per rectum
Advantages
Access to GI abosption in unconscious or vomiting patients
Drug can be recovered before absorption is complete
Disadvantages
Animals may not willingly retain the drug
Process
As for oral without mechanical preparation by stomach
Drug Distribution
Physiologic "spaces" (Figure)
Vascular space (plasma / plasma water + RBC's)
There is also "tissue space"
Size
~ 7% of body weight
Equilibria
between water and various plasma / serum proteins
between ionized and unionized drug
between plasma and cells
Distribution in 10 to 30 minutes (mixing)
Extracellular Space (exists in both vascular and tissue spaces)
Size
~ 15 - 20% of body weight
includes extracellular fluid in bloodstream (plasma)
Equilibria
between water and proteins
between ionized and unionized drug
Distribution in 30 minutes to 1.5 hours
Intracellular space (exists in both vascular and tissue spaces)
Size
~ 35 - 45% of body weight
Equilibria
between ionized and unionized drug
intracellular pH different (lower) than extracellular
Distribution in 30 minutes to 12+ hours
Reserved spaces
Special barriers between plasma and tissue fluid
CSF
aqueous humor
prostatic fluid
Distribution in minutes to never
Movement between spaces
Vascular space (extracellular) to tissue (extracellular) space
Transcytotic
Endothelial junctions with inflammation
Diffusion through endothelial cell membranes
Carried in cells or on proteins in very special circumstances
Extracellular space (of tissue) to intracellular space (of tissue)
Diffusion through lipid bilayer of cells
Vascular extracellular space to vascular intracellular space (drugs can move into RBCs and WBCs)
Diffusion through lipid bilayer of cells
WBCs may actively acquire certain drugs
Diffusion limited distribution
Diffusion is usually slow (relative to mixing and distribution within vascular system)
Tissue distribution of the drug controlled by the ability of the drug to diffuse into the tissue
Blood flow limited distribution
Diffusion can be VERY rapid
Tissue distribution of the drug controlled by the rate of drug delivery to the tissue (total mg/minute) which is controlled by blood flow / gram of tissue
Brain and liver concentration rise faster than muscle or fat
Enterohepatic circulation
How does it work?
Drug or it’s Phase II conjugate excreted in bile
Drug reabsorbed or Conjugate cleaved by bacteria and drug reabsorbed
What does it mean?
Elimination rate for drug is lower in spite of efficient hepatic metabolism / secretion
Volume of distribution of the drug is higher
Why do you care?
Interrupt to improve drug elimination
Insecticide poisonings, phenobarbital overdoses, etc.
Mammary excretion
How does it work?
Non-ionic Diffusion (lipid solubility and size dependence)
Inflammation reduces barriers to penetration (masititis)
Ion trapping
normal milk pH = 6.6 (slightly acidic versus blood).
Mastitic milk pH is slightly higher
Why do you care?
May affect treatment of some bacterial infections of the mammary gland
Nursing animals may be exposed to toxic concentrations of drug in the milk.
Salivary excretion
How does it work?
Non-ionic diffusion into salivary secretions
Drug in saliva passes into GI tract
What does it mean?
Ruminants
Recycle certain drugs like enteroheptic circulation (prolonged elimination)
Trap certain drugs in the rumen pH dependent (enhanced elimination)
Non-ruminants
Little effect on elimination possible
Drug Elimination
Biotransformation
Conversion of a drug entity to a metabolite
Usually inactivates the drug
generally reduces drug activity
MAY activate the drug
Major route of elimination for lipid soluble and protein bound drugs (because other routes are not efficient).
Chemical mechanisms
Oxidation, hydroxylation, hydrolysis, reduction, conjugation (acetylation, glucuronidation, sulfation, etc.)
Efficiency (rate)
Metabolic activity for a specific drug
Blood flow to the organ
Health of the organ and health of the circulatory system
Organs involved
Liver (most important for most drugs)
Lungs (especially for autocoids)
Kidneys
Biliary excretion
Active secretion
Drugs with molecular weights > 300
mostly conjugates of original drug
Passive secretion
Drugs with molecular weights < 300
biliary concentrations similar to plasma water
Renal excretion
Overall renal elimination can be a combination of three processes:
(Glomerular filtration + tubular secretion) - passive reabsorption = renal elimination
Glomerular filtration
passive elimination of drug dissolved in plasma water
ionized and unionized
NOT protein bound drug
Tubular secretion
energy dependent excretion by proximal kidney tubule
organic acid and organic base pumps
includes protein bound drugs
competition between acids or between bases
Passive reabsorption
drug movement from renal tubule back to blood stream
lipid soluble drugs
unionized drug molecules
normal concentrating ability
Passive reabsorption can be reduced by disease (accidental) or by therapy (intentional)
increases elimination rate of the drug
DOES NOT WORK if reabsorption is not an important part of normal elimination
How?
high urine production
reduced tubular concentations of EVERYTHING
reduced contact time with epithelium
alter urine pH
ionized drug cannot be reabosrbed
acids trapped in alkaline urine
bases trapped in acid urine
renal elimination of aspirin can go from 2% to 30% of total elimination
Pharmacokinetic Modeling
Volume of Distribution
The volume of fluid that "appears" to contain the amount of drug in the body (based on the plasma concentration - See Figure 1).
Partially determines the relationship between dose and plasma concentration
Defines the volume of fluid that must be processed by organs of elimination
Roughly describes "tissue penetration"
May not equal an actual physiologic space (See Figure 2).
Equation(s)
One compartment plot (Figure 6)
Cp0 is the plasma concentration at time = 0 (IV adminsitration ONLY)
Units
Liters or milliliters describing whole animal
Liters/kg or milliliters/kg
Table 2: Representative (theoretical) volumes of distribution.
Clearance
(e.g., Hepatic Clearance)The volume of plasma water cleared of the drug during a specified time period.
Equation(s):
Organ clearance is calculated by determining the flow (Q) and the efficiency of extraction
Total body clearance (Clt) is the sum of all organ clearances
Experimentally we determine clearance by determining the Volume of distribution and the elimination rate constant (Figures 5-7)
Units:
Volume / unit time (l/hr, l/min, ml/hr etc) describing whole animal
Volume / kilogram / unit time (l/kg/hr, ml/kg/min etc.)
Rate constant of elimination
The fraction of the volume of distribution cleared per unit time (or)
The slope of the natural log plot of the drug concentration versus time profile (Figure 7)
One compartment plot (Figure 7)
Equation(s)
"Produced" by the relationship between the volume of distribution and the total clearance:
Determined from the slope of the "elimination portion" of the drug concentration vs time profile (curve).
Units
/hr, /min, hr-1, min-1
Figure 6: Determining the "pharmacokinetics" of the fish tank.
Multiply the concentration X the Vz to determine the amount in the body at each time point. Subtract the amount in the body at one time point from the amount in the body at the PREVIOUS time point to determine the amount eliminated during the time "interval."
Although the amount eliminated from the body is less and less for each time interval, the FRACTION of the amount eliminated during each interval is constant. This is demonstrated by the semi-log plot.
Elimination half-life
The time for elimination of one half of the total amount in the body.
Units
Hours or minutes
Application(s)
Tissue Residues
At 5 x T1/2 97% has been eliminated
Make sure you use the longest half-life (gentamicin example)
Metabolites may be more important than the drug
Extremely slow absorption from injection site may be the primary cause of residues.
Approach to steady state
Steady state exists when defined plasma concentrations (peak, average, trough) are identical following each administered dose during chronic therapy.
At 5 x T1/2 concentrations are 97% of steady state values no matter what the dose and interval.
Digoxin, maximum effects of digoxin may appear as late as 8 days after therapy is initiated
The relationship between dose interval and half-life determines the need for a loading dose.
A loading dose is an itital dose of drug given to shorten the time to reach the steady-state concentrations.
Absorption rate constant
The absorption rate constant describes the rate of drug movement (oral, IM, SC, etc.) from the dose to the circulatory system.
Units
/hr, /min, hr-1, min-1
Application
In combination with other factors, ka determines the time required to reach the peak concentration (Cmax) following a dose of drug and the peak drug concentration.
Fraction of dose absorbed (F)
When a drug is administered by any route OTHER than IV, it is rare that the entire dose is absorbed
Oral
Destroyed in GI tract, passes out in feces before it is absorbed, binds to ingesta, etc.
IM
Hydrolysis of drug in tissue, drug binding to injection site, abcess formation, etc.
Units
Either percentage of dose or fraction of the dose (59% = 0.59)
Application
The fraction of the dose absorbed determines a drug’s bioavailability (how much gets into the blood stream). Bioavailability is a common measure used to compare two different drug formulations (tablets vs. elixir) or to compare products sold by two different manufacturers (trade name drugs vs. generics).
Bioequivalence
Two drug products are bioequivalent if the nature and extent of therapeutic and toxic effects are equal following administration
Although similar and related, equal bioavailability (F) does not guarantee bioequivalence.
Pharmacokinetic Models
Physiologic models
Attempt to describe the actual events which control drug absorption, distribution, and elimination
Derived from measurements of drug concentrations in specific fluids (bile, portal and hepatic veins, tissue fluids, urine, etc.).
Deal with an organ, a tissue or an organ system
Combined to describe functions and processes
Mathematic models
Attempt to accurately predict the time course of drug concentrations in one (usually blood or plasma) or two (urine as well) body fluids. Predictions are generally made for tissues which can be sampled from intact patients.
"Pharmacokinetics" on package inserts represent these kinds of model.
Modeling begins with a single dose experiment:
A dose of drug is administered, samples are taken at timed intervals after dosing, samples are analyzed for drug concentrations.
Drug concentrations are then plotted and analyzed mathematically to determine the drug’s clearance, the rate constant of elimination, half-life, and the volume of distribution of the drug.
Body compartments
DO NOT ASSUME THAT ANY REAL PHYSIOLOGIC BODY SPACE IS BEING DESCRIBED BY MATHEMATICAL MODELS.
Central Compartment
Blood volume
Organs of eliminationPeripheral compartment
Muscle
Subcutis
Lung tissueDeep compartments
Fat (poor blood supply, lipid soluble drugs)
Kidneys (aminoglycosides)
THE NUMBER OF COMPARTMENTS IS NOT A PHARMACOLOGICAL PROPERTY OF THE DRUG.
N compartments represents the amount of detail available considering the "experimental conditions".
Number of samples
Sample timing
Obesity, starvation, dehydration, etc.Difference in rates of distribution into various tissues (2 volumes cannot be separated if individual rate constants are similar).
N compartments may be arbitrarily reduced if the level of detail available is unnecessary.
Most clinical monitoring reduces "truth" to a one compartment open model
Figure 10: Linear and semi-logarithmic plots of Pharmacokinetic models. The two compartment models were generated by INCLUDING samples at 5, 15, 25 and 30 minutes.
Dose Dependent Behavior
For most drugs (99%), it is logical to assume that the relationship between the dose we give and the concentration(s) that the dose produces in the body are linear. (We double the dose, the concentrations double, the effects double). The PHARMACOKINETICS of these drugs are said to be dose-independent.
Occassionally, drug dosing behave differently:
Although we have described pharmacokinetics as being "first-order" throughout these notes, the real absorption and elimination behavior of drugs obeys Michaelis-Menton kinetics. That is, first-order at "low" doses (most drugs at therapeutic doses), zero-order at "high" doses and mixed-order in between.
Order
ExampleFirst Order (The pharmacokinetics of MOST drugs is first order at therapeutic doses.)
A fraction the dose of drug is absorbed per unit time
A fraction of the amount of drug in the body is eliminated per unit time.
Plots
Arithmetic plots of concentration vs. time will be a curve with a positive deflection (slope becomes less negative with time).
A semi-log plot will be a straight line or series of straight lines (multiple compartments).
As long as elimination remains first order:
There will be a half-life of elimination
Increasing or decreasing the dose will produce a proportional increase or decrease in the plasma concentration and in drug effect.
A steady state will be achieved for ANY rate of drug administration.
Zero order (special dose forms, high concentrations of some drugs).
A constant amount of drug is absorbed per unit time (or)
A constant amount of drug is eliminated per unit time
Plots
Arithmetic plots of concentration vs. time will fall on a straight line
Semi-log plots have a negative deflection (slope becomes more negative with time)
If elimination is zero order:
Drug may accumulate infinitely
There is no "half-life"
|
Abbreviation |
Term |
Units |
Definition |
|
Clt |
Clearance, Total |
l/hr/kg |
The sum of all individual organ clearances. Usually determined by plasma sampling. |
|
Clr |
Clearance, Renal |
l/hr/kg |
The clearance "performed" by the kidney. |
|
Clh |
Clearance, Hepatic |
l/hr/kg |
The clearance "performed" by the liver. |
|
Cmax |
Peak plasma concentration |
mg/ml (or) mg/liter |
Highest plasma concentration achieved following a single non-intravenous dose of a drug. |
|
Cp |
Plasma concentration |
mg/ml (or) mg/liter |
Plasma concentration, may be folled by a subscript for time (Cpt – see Cp0 below) |
|
Cp0 |
Plasma concentration at time zero |
mg/ml (or) mg/liter |
The plasma concentration at zero time. Determined by extrapolating the plasma concentration versus time "curve" back to the Y (concentration) axis. |
|
F |
Fraction of dose absorbed |
None or % |
Portion of a non-intravenous dose of drug that reaches the systemic circulation. |
|
T1/2 |
Half life of elimination |
hrs (or) minutes |
Time required to eliminate 50% of any amount of drug from the body. |
|
Tmax |
Time of the peak plasma concentration |
hrs (or) minutes |
The time that the Cmax (above) is achieved following a single non-intravenous dose of a drug. |
|
Vz |
Volume of distribution |
L/kg |
The volume calculated using the intercept of the "z" portion of a curve and the Y axis. |
|
Equation |
Units |
Application |
|
|
hr-1, /hr, min-1, /min |
Calculates slope of a line for a natural log plot of plasma concentration versus time data. |
|
|
liters, milliliters if dose is in mg; liters/kg or milliliters/kg if dose is in mg/kg |
Extrapolate plasma concentration versus time "curve" back to the Y (concentration) axis. The intercept is Cp0. The dose is the intravenous bolus dose. |
|
|
mg or mg/kg |
You can calculate the amount of drug in the body at any time =t if you know the volume of distribution and the plasma concentration at that time Cpt. |
|
|
L/hr/kg or l/hr |
Clearance is calculated following a pharmacokinetic experiment as the product of volume of distribution and elimination rate constant. |
|
|
hr-1, /hr, min-1, /min |
In the animal the elimination rate constant is the RESULT of the total body clearance of the drug and the volume of distribution into which the drug is distributed. (lz is not usually calculated this way). |
|
5 x T1/2 |
hrs, min. |
Five times the elimination half-life determines: 97% of the time to reach steady state The time to eliminate 97% of the drug |